Hepatitis
Hepatitis 09/03/2010
Treatment interruptions “particularly hazardous” for those coinfected with hep B
Increases in HBV viral load and accelerated immune deficiency were documented among coinfected individuals partaking in structured drug holidays in the study.
Hepatitis 09/03/2010
Vertex maps out combo drug game plan for treating hepatitis C
Vertex, the Cambridge, MA-based company with operations in San Diego, offered a glimpse last week into its strategy for a two-drug combo that could significantly change hepatitis C treatment.
Hepatitis 04/03/2010
Groundbreaking research to find vaccine for hepatitis C
The research team is trying to find a vaccine by examining what it is that is special about the white blood cells of people who are naturally immune to the disease.
Hepatitis 03/03/2010
Abacavir does not compromise effectiveness of hepatitis C treatment, but zidovudine may reduce response
Using a NRTI backbone containing abacavir was not associated with poorer response to interferon-based therapy for hepatitis C in HIV/HCV coinfected patients. However, backbones containing zidovudine and possibly didanosine were associated with a lower likelihood of achieving a sustained response.
Hepatitis 03/03/2010
Enanta nominates EDP-239 as lead development candidate for NS5A HCV inhibitor program
EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.
Hepatitis 02/03/2010
Abbott and Enanta announce advancement of hepatitis C collaboration
Initiation of Phase 2 clinical trial investigating three individual HCV antivirals.
Hepatitis 01/03/2010
Vertex broadens its commitment to improving HCV care with clinical trial to evaluate combination regimens based on oral antiviral therapies
Trial will evaluate safety and SVR rates with multiple 12-week response-guided regimens of telaprevir/VX-222-based combination therapy, including two-drug regimens of telaprevir and VX-222; Interim clinical data expected in the second half of 2010; Multiple clinical trial sites in the U.S. to enroll patients.
Hepatitis 01/03/2010
HIV, HIV/HCV coinfection double the risk for stroke
Patients who are coinfected with HIV and hepatitis C virus have a markedly increased risk for stroke — a finding that indicates that vascular risk factors need to be controlled in those with these infections.
Hepatitis 01/03/2010
IL28B gene variation predicts response to hepatitis C treatment: will it change treatment of co-infection?
Variations in the IL28B gene that have recently been linked to better treatment response among people with chronic hepatitis C virus infection may also predict recovery in HIV/HCV-coinfected people.
Hepatitis 26/02/2010
Avila aims to trump Vertex with drug that hits hepatitis C virus and won’t let go
Avila Therapeutics can’t be accused of thinking too small. This Waltham, MA-based startup is on a quest to show it has the scientific chops to build a better drug than one of Boston’s anchor biotech companies—Vertex Pharmaceuticals.
Hepatitis 26/02/2010
Resistance likely to develop with new hepatitis C drugs
Addition of drugs to interferon and ribavirin treatment improves efficacy.
Hepatitis 25/02/2010
Regulus could get $150M from expanded partnership with GlaxoSmithKline for hepatitis C work
Regulus is a joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals. It develops drugs that use microRNA technology, which can turn parts of genes on or off to treat diseases.
Hepatitis 25/02/2010
ANA598 demostrates 73% cEVR in combination with interferon and ribavirin
No viral rebound observed during 12 weeks of ANA598 dosing; Positive safety data with AE profile comparable to control group.
Hepatitis 24/02/2010
Advance reported in hepatitis C therapy
U.S. scientists say they've found two genetic alterations linked to an enzyme deficiency that may help patients remain anemia-free during hepatitis C therapy.
Hepatitis 23/02/2010
Humanized mice come down with hepatitis B and C
Yet another group of lab mice have been "humanized" so researchers can seek cures for infections that normally only strike people.
Hepatitis 23/02/2010
Successful hepatitis C treatment reduces HIV disease progression and non-liver-related mortality
HIV/HCV-co-infected people who achieve a sustained virological response to interferon-based therapy not only reduce their risk of death due to liver disease, but also experience less HIV disease progression and have a lower rate of non-liver-related death.
Hepatitis 20/02/2010
Shorter treatment may be adequate for genotype 1 hepatitis C if started during acute infection
HIV positive gay/bisexual men with acute hepatitis C virus (HCV) coinfection responded as well to 24 weeks of interferon-based therapy as they did to 48 weeks, even though most had hard-to-treat HCV genotypes 1 or 4.
Hepatitis 20/02/2010
Does liver fibrosis progress faster in people who have HIV when they acquire hepatitis C?
HIV positive men who subsequently became infected with hepatitis C virus appeared to have a suspiciously rapid rate of liver disease progression in the European NEAT study.
Hepatitis 20/02/2010
HBV DNA not detected in semen of men with chronic hepatitis B successfully treated with nucleotide analogs
HIV positive and negative men with chronic hepatitis B who achieved undetectable serum HBV DNA during treatment with nucleotide analogs such as tenofovir also cleared HBV genetic material in their semen, suggesting a reduced risk of sexual transmission.
Hepatitis 19/02/2010
Pharmasset announces complete enrollment of RG7128 Phase 2b clinical study
Roche initiating additional clinical studies with RG7128 - INFORM studies delayed.
More...
